SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant momentum driven by high trading volume, whale accumulation, and speculation surrounding potential major corporate partnerships. Community sentiment remains highly divided, with many traders riding the volatility of the recent price surge while others express skepticism regarding potential supply releases and the sustainability of the current rally.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is currently seeing significant community activity as investors weigh recent reports of a bank acquisition and ongoing speculation regarding potential institutional partnerships. While some traders are expressing frustration over price volatility and volume, others are actively accumulating based on the project's high-speed blockchain claims and its potential role in future financial infrastructure.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is facing intense volatility as the stock undergoes a sharp correction, triggering heavy debate among traders about whether the current price levels represent a significant buying opportunity or a deeper valuation trap. While some market participants are focused on potential institutional accumulation and long-term infrastructure demand, others are wary of the aggressive insider selling and recent technical breakdowns that have eroded confidence.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders discuss its transition from a niche digital asset into a 'phygital' powerhouse, highlighted by widespread retail presence in major stores and the recent launch of a Visa-backed spending card. The community is actively debating the project's long-term utility and potential for price momentum, with many investors using current market fluctuations as a buying opportunity to DCA into their positions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company navigates a complex turnaround, with the community closely tracking potential Schedule III rescheduling catalysts and the impact of the new Medicare CBD pilot program. While some shareholders express frustration over past management decisions and performance, many are actively monitoring the stock for a trend reversal, heavily debating the timing of regulatory milestones versus ongoing sector volatility.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is trending as investors react to a series of strategic milestones, including a new feasibility study for a major Texas power hub and the continued expansion of its microreactor development pipeline. The community is actively debating the company's long-term commercialization timeline and the broader role of advanced nuclear technology in meeting the surging electricity demands of AI data centers.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

IMSR is trending as investors react to the companys dual Other Transaction Agreements with the U.S. Department of Energy, which aim to accelerate the commercialization of its integral molten salt reactor technology. Community discussions are heavily focused on the stock's potential for a significant valuation rerating as it gains federal support, with bulls drawing comparisons to the market trajectory of established sector peers while debating the company's timeline for achieving reactor criticality.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is under pressure following fourth-quarter earnings that, despite beating consensus estimates, failed to satisfy investor expectations amidst ongoing market volatility. The community is actively discussing the broader banking sector's sensitivity to potential regulatory credit card interest rate caps and shifting economic conditions as traders navigate the fallout from mixed earnings reports across the financial space.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the successful Artemis II mission fuels massive investor enthusiasm for the space infrastructure sector, with the community closely tracking the stock's momentum following significant contract-related developments. Traders are actively debating whether this represents a sustainable long-term breakout or a temporary rally, while excitement builds around the company's expanding role in lunar exploration and upcoming mission milestones.

Ares Capital Corp is a traded fund invests in companies located in the United States and Canada with an EBITDA of USD 10 - 250 million. The fund targets companies operating in the fields of health care services, software & services, consumer durables & apparel, energy, food & beverage and retail. It provides financing in the form of debt and equity for mezzanine, buyouts, acquisitions, recapitalizations, restructurings, rescue financing, growth capital and general refinancing with an investment size ranging from USD 10 - 500 million. The fund acquires controlling Interest. It acts as lead investor and takes a seat on the board of directors.

Ares Capital Corp

Ares Capital Corporation

Ares Capital is currently attracting significant attention as investors weigh the stability of its long-standing dividend track record against broader concerns surrounding the private credit sector and potential borrower stress. While some community members view the current share price as a bargain and are actively accumulating shares to capture high yields, others express caution, citing macroeconomic volatility and the risks associated with high exposure to complex loan structures like PIK interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025.&nbsp;</li><li>The company added on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development and commercial milestone-based payments.&nbsp;</li><li>CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic.</li></ul>Shares of Cue Biopharma, Inc. (CUE) is on track to record its best session to date, if gains hold, after the company announced earlier this week that it will receive $7.5 million as milestone payment from an agreement with Boehringer Ingelheim.CUE stock is up 77% at the time of writing.<h2 class="st-heading-2">Cue- Boehringer Ingelheim Deal</h2>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025 &nbsp;to develop and commercialize Cue Biopharma’s CUE-501 product candidate for autoimmune diseases.Under the deal, Cue received an upfront payment of $12 million and is eligible to earn up to about $345 million in research, development and commercial milestone-based payments, as well as royalty payments on net sales.The company now expects a $7.5 million payment in May 2026. Cue Biopharma also said on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development, and commercial milestone-based payments.CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic. In February, the company said that its preclinical data demonstrated that CUE-401 was well tolerated with no adverse events.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed optimism about the rally after a quiet period. “This is starting to get interesting,” they wrote<stembedurl>https://www.stocktwits.com/topstockalerts/message/649975686</stembedurl>Another user highlighted the possibility of additional payments under the deal.<stembedurl>https://www.stocktwits.com/Aburose/message/649968775</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cue Biopharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?

Cue now expects a $7.5 million payment from Boehringer Ingelheim in May 2026.

Equity

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.read more...

Get Ready for the Weekend with One of these Strong Runners

Today’s market action is dominated by a bunch of listings we’ve covered this week, plus a few fresh faces, like Cue Biopharma (NASDAQ:CUE), which is running strong after announcing, on Wednesday, that it will receive $7.5 million preclinical milestone payment for its agreement with Boehringer Ingelheim, while Xiao-I (NASDAQ:AIXI) has been in play since providing an update on its Apple (NASDAQ:AAPL) patent infringement lawsuit. $SKYQ, $KBLB, $UCAR, $ELAB, $CUE, $AIXI, $AAPL, $CREG, $RAYA

Shares of Cue Biopharma (CUE) fell 8% in extended trading hours on Friday after the company announced that its top leader Usman Azam has stepped down as president and CEO, effective March 26.Azam also resigned from his role as a director of the company. Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri, and served merely six months in the role. &nbsp;<h2 class="st-heading-2">New CEO</h2>Lucinda Warden has been appointed interim president and CEO, the company said. Warden served as Cue Biopharma’s chief financial and business officer since Feb. 2026, and previously as Cue Biopharma’s chief business officer from Sept. 2024 until Feb. 2026.Prior to working with Cue, Warden was employed with Johnson &amp; Johnson and Janssen Biologics.<h2 class="st-heading-2">Cue Pipeline</h2>Boston, Massachusetts-headquartered Cue Biopharma is now looking to progress CUE-401 into clinical trials by the second half of this year. The investigational drug is the company’s lead asset for the treatment of autoimmune and inflammatory diseases. In preclinical studies, CUE-401 was well tolerated with no adverse events observed.In November, Cue also entered into a collaboration and license agreement with ImmunoScape, Pte. Ltd, a biotechnology company, to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.Under the agreement, ImmunoScape will develop a novel Seed-and-Boost immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers, with ImmunoScape’s proprietary T cell receptors.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CUE Stock Slips As CEO Leaves After Just Six Months In Role

Usman Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri.  

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

CUE
Cue Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CUE News

CUECue Biopharma Inc